Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 Disease) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

CLN2 disease is a lysosomal storage disorder in the neuronal ceroid lipofuscinosis (NCL) family caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1 (TPP1), resulting from mutations in the TPP1 gene. CLN2 disease typically presents with seizures between the ages of 2 and 4 years, with language delays increasingly reported as a preceding symptom. Other symptoms reported at presentation included developmental delay, motor dysfunction, ataxia, behavioral abnormalities, and dementia. In later stages, it is characterized by a progressive decline of visual and cognitive functions, and it is usually fatal in early adolescence. Diagnostic delays of over 2 years are not uncommon for patients with CLN2 disease, and these coincide with the period during which rapid disease progression begins. Aside from limited awareness of CLN2 disease, several other factors may delay its diagnosis. Early symptoms such as seizures and language delays are also associated with many different diseases. Because the presenting symptoms of CLN2 disease are nonspecific, there is often a diagnostic delay, which can result in delays in providing disease-specific treatment, including complex multidisciplinary care and enzyme replacement therapy (ERT) cerliponase alfa.

Thelansis’s “Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 Disease) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 Disease) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 Disease) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 Disease) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 Disease) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033